Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose
NCT02130011 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2015-10-06
Summary
This study will prospectively collect patients undergoing the standard CROSS regimen in the neoadjuvant setting of the treatment for gastro-oesophageal cancer. The investigators will focus on the potential geometric differences between the OAR and target volume on the initial planning CT and on the kilovolt (kV) cone-beam computed tomography (CBCT). They expect a potential difference in the abdominal part of the planned target volume (PTV) and/or gastro-oesophageal junction part. Furthermore, the impact of gastric filling , potential tumor regression and the accuracy of 5 mm PTV margin in the thoracic PTV will be monitored.
Conditions
- Adenocarcinoma
Interventions
- OTHER
-
with feeding/fluid instruction
No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
Sponsors & Collaborators
-
Maastricht University Medical Center
collaborator OTHER -
Maastricht Radiation Oncology
lead OTHER
Principal Investigators
-
Philippe Lambin, MD, PhD · Maastricht Radiation Oncology
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2014-11-30
- Completion
- 2015-09-30
Countries
- Netherlands
Study Locations
More Related Trials
-
Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction
NCT00374985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
NCT03474341 ·Status: UNKNOWN
-
Organ Motion and Early Tumor Response Measurement
NCT02139488 ·Status: COMPLETED
-
Chemoradiation and Panitumumab for Esophageal Cancer
NCT01077999 ·Status: COMPLETED ·Phase: PHASE2
-
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
NCT00911092 ·Status: COMPLETED ·Phase: PHASE4
-
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
NCT04046575 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00551759 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
NCT00021320 ·Status: COMPLETED ·Phase: PHASE2
-
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
NCT01348217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
NCT01107639 ·Status: COMPLETED ·Phase: PHASE3
-
Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma
NCT00230451 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Cancer Therapy on Myocardial Function in Patients With Esophagus Cancer
NCT03619317 ·Status: UNKNOWN
-
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00022139 ·Status: COMPLETED ·Phase: PHASE2
-
Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis
NCT01525953 ·Status: COMPLETED
-
Feasibility Study of Fiducial Markers in Oesophageal Cancer
NCT02403050 ·Status: UNKNOWN
-
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
NCT03064490 ·Status: COMPLETED ·Phase: PHASE2
-
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
NCT01333033 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung
NCT03051802 ·Status: TERMINATED ·Phase: NA
-
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
NCT07000253 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest
NCT00433524 ·Status: COMPLETED ·Phase: NA
-
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
NCT01291823 ·Status: UNKNOWN ·Phase: PHASE2
-
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
NCT00757172 ·Status: COMPLETED ·Phase: PHASE2
-
OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma
NCT03429816 ·Status: COMPLETED ·Phase: NA
-
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
NCT00711412 ·Status: COMPLETED ·Phase: PHASE2